Envista Holdings (NVST)
NYSE:NVST
Want to see NVST full AI Analyst Report?
NVST Stock Chart & Stats
$27.84
-$0.72(-3.69%)
At close: 4:00 PM EST
$27.84
-$0.72(-3.69%)
Day’s Range― - ―
52-Week Range$17.78 - $30.42
Previous CloseN/A
Volume757.64K
Average Volume (3M)3.65M
Market Cap
$3.83B
Enterprise Value$4.34B
Total Cash (Recent Filing)$1.08B
Total Debt (Recent Filing)$1.59B
Price to Earnings (P/E)57.0
Beta1.01
Next Earnings
Aug 05, 2026EPS Estimate
0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.42
Shares Outstanding162,727,920
10 Day Avg. Volume4,288,807
30 Day Avg. Volume3,654,481
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)1.17
Price to Sales (P/S)1.34
P/FCF Ratio15.83
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue1.55
Enterprise Value/Gross Profit2.80
Enterprise Value/Ebitda12.69
Forecast
1Y Price Target
$29.40Price Target Upside5.60% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)1.43
Revenue Forecast (FY)$2.86B
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthSustained ~55% gross margins and recent +100bps expansion reflect durable product mix advantages (high‑margin consumables, implants, imaging). That margin base provides structural operating leverage, supports reinvestment and resilience to modest cost headwinds over months.
Robust Cash GenerationHealthy TTM FCF and management's target of ~100% conversion signal that reported profits are largely backed by cash. This strengthens funding for capex, tuck‑ins and buybacks, reduces refinancing risk, and preserves strategic optionality over the next several quarters.
Diverse Product Portfolio & InnovationMultiple high‑growth product lines, a large installed imaging base and recent launches (implants, ortho, AI imaging) create recurring consumables demand and conversion opportunities. Innovation plus installed base-driven consumables supports steady revenue mix and durable competitive positioning.
Bears Say
Thin Net Margins & Earnings VolatilityDespite margin expansion at the gross level, net margins remain very thin and historical earnings swung to losses recently. Thin bottom‑line buffers and volatile profitability constrain reinvestment capacity and increase execution risk if top‑line or cost trends reverse over the next few quarters.
China Implant Destocking & VBP Timing RiskChannel inventory reductions ahead of volume‑based procurement introduce structural timing risk: VBP can compress near‑term demand and margins while timing and scope are uncertain. For a business with meaningful implants exposure, this can depress growth and complicate forecasting for several quarters.
Leverage, CapEx And Tariff PressureMaterial absolute debt levels alongside elevated capex for new facilities and recurring tariff costs reduce near‑term financial flexibility. Negative Q1 FCF driven by expansion spending and ongoing tariff headwinds can strain liquidity if revenue or margin momentum weakens over the coming quarters.
Envista Holdings News
NVST FAQ
What was Envista Holdings’s price range in the past 12 months?
Envista Holdings lowest stock price was $17.78 and its highest was $30.42 in the past 12 months.
What is Envista Holdings’s market cap?
Envista Holdings’s market cap is $3.83B.
When is Envista Holdings’s upcoming earnings report date?
Envista Holdings’s upcoming earnings report date is Aug 05, 2026 which is in 64 days.
How were Envista Holdings’s earnings last quarter?
Envista Holdings released its earnings results on May 06, 2026. The company reported $0.36 earnings per share for the quarter, beating the consensus estimate of $0.312 by $0.048.
Is Envista Holdings overvalued?
According to Wall Street analysts Envista Holdings’s price is currently Undervalued.
Does Envista Holdings pay dividends?
Envista Holdings does not currently pay dividends.
What is Envista Holdings’s EPS estimate?
Envista Holdings’s EPS estimate is 0.34.
How many shares outstanding does Envista Holdings have?
Envista Holdings has 162,727,920 shares outstanding.
What happened to Envista Holdings’s price movement after its last earnings report?
Envista Holdings reported an EPS of $0.36 in its last earnings report, beating expectations of $0.312. Following the earnings report the stock price went down -10.27%.
Which hedge fund is a major shareholder of Envista Holdings?
Currently, no hedge funds are holding shares in NVST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Envista Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.40 (5.60% Upside)
$29.40 (5.60% Upside)
Blogger Sentiment
Bullish
NVST Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.57%
12-Months-Change
Fundamentals
Return on Equity
2.18%
Trailing 12-Months
Asset Growth
2.04%
Trailing 12-Months
Company Description
Envista Holdings
Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
NVST Company Deck
NVST Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed broad-based operational and commercial progress: healthy top-line growth (9.5% core, ~4% normalized), margin expansion (gross margin +100 bps, EBITDA margin +120 bps), strong EPS improvement (+50%), meaningful new-product momentum, accretive tuck-in M&A, and continued capital returns (incremental $300M buyback). Key near-term headwinds include China implant destocking ahead of VBP, elevated tariff costs (~$11M), Q1 negative FCF due to CapEx, and geopolitical-driven inflation/freight risks — all of which management has identified and presented mitigation plans for. Overall, the positives on growth, margins, product launches and capital allocation materially outweigh the manageable near-term challenges.View all NVST earnings summariesNVST Revenue Breakdown
63.99% Specialty Products & Technologies
36.01% Equipment & Consumables
NVST Stock 12 Month Forecast
Average Price Target
$29.40
▲(5.60% Upside)
Technical Analysis
DENTSPLY SIRONA
―
Disc Medicine
―
Clover Health Investments
―
AbCellera Biologics
―
Bausch + Lomb Corporation
―
Ownership Overview
0.79% Insiders
37.53% Mutual Funds
29.91% Other Institutional Investors
6.27% Public Companies and
Individual Investors